Table 4.
Two-year persistent versus non-persistent individuals among GLP-1RA users
| Persistence | Non-persistence | p value | |
|---|---|---|---|
| Without HbA1c measurement | |||
| N = 1734 (%) | 840 (48.4) | 894 (51.6) | |
| Death (n, %) | 23 (2.8) | 20 (2.3) | 0.6060 |
| Acute myocardial infarction (n, %) | 15 (1.8) | 8 (0.9) | 0.1580 |
| Stroke (n, %) | 23 (2.8) | 13 (1.4) | 0.0880 |
| Heart failure hospitalization (n, %) | 8 (0.9) | 8 (0.9) | 1.0000 |
| Severe hypoglycaemia with hospitalization (n, %) | – | – | – |
| With HbA1c measurement | |||
| N = 985 (%) | 652 (66.2) | 333 (33.8) | |
| Mean HbA1c (SD) | 7.5 ± 1.31 | 7.4 ± 1.55 | 0.1420 |
| HbA1c ≤ 7.0% (n, %) | 355 (54.5) | 159 (47.8) | 0.0540 |
| Reduction in HbA1c (n, %) | 265 (40.6) | 62 (18.6) | < 0.0001 |
GLP-1RA GLP-1 receptor agonists